Previous- Procalcitonin – a valuable diagnostic marker in meningococcal disease

Graham D Mills, Hamish M Lala, Michael R Oehley, Angela B Craig, Kevin Barratt, Dell Hood, Craig N Thornley, Annette Nesdale, Noel E Manikkam, Paul Reeve,

Waikato, Auckland, and Hutt Valley District Health Boards, New Zealand

Background: Some patients with meningococcal disease (MCD) seeking medical attention create a diagnostic dilemma for clinicians due to the non-specific nature of their presentation. We have assessed the diagnostic accuracy of procalcitonin within the emergency department (ED), to clarify its role in the evaluation of MCD.

Methods: Two overlapping cohorts have been studied. Procalcitonin levels were measured in a cohort of patients with confirmed MCD diagnosed within the current New Zealand serogroup B epidemic, to assess the sensitivity of procalcitonin. In the second cohort, a large consecutively recruited ED population of febrile patients, enabled specificity and likelihood ratios of procalcitonin to be evaluated.

Would you like to support the work of the Foundation?

Contact us for more information, or simply make a donation.